Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 2, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1756-8722-2-21
Keywords
-
Categories
Ask authors/readers for more resources
Cisplatin depletes MGMT and increases the sensitivity of leukemia cells to temozolomide. We performed a phase I study of cisplatin and temozolomide in patients with relapsed and refractory acute leukemia. Fifteen patients had AML, 3 had ALL, and 2 had biphenotypic leukemia. The median number of prior chemotherapy regimens was 3 (1-5). Treatment was well tolerated up to the maximal doses of temozolomide 200 mg/m(2)/d times 7 days and cisplatin 100 mg/m(2) on day 1. There was one complete remission in this heavily pretreated patient population. Five of 20 (25%) patients demonstrated a significant reduction in bone marrow blasts.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available